Literature DB >> 186554

Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. I. Rapid evolution of encephalomyocarditis virus infection.

I Gresser, M G Tovey, M E Bandu, C Maury, D Brouty-Boyé.   

Abstract

The role of interferon in the pathogenesis of encephalomyocarditis (EMC) virus infection was determined by treating mice with potent, partially purified sheep anti-mouse interferon globulin. In control mice, EMC virus was present in low titers in various visceral organs but attained high titers in the brain towards the 4th to 5th day, at which time mice died with signs of central nervous system disease. In mice treated with anti-mouse interferon globulin, virus was present in high titer in visceral organs 24--36 h after viral inoculation and virtually all mice were dead by 45 h. This rapid evolution of EMC virus infection was not observed in mice treated with the globulin fraction prepared from a normal sheep, from a sheep exhibiting a low anti-mouse interferon-neutralizing titer, nor from a sheep having a high titer of antibody to human leukocyte interferon. The experimental results indicated that anti-interferon globulin neutralized the interferon liberated by virus-infected cells, thus permitting extensive virus multiplication in several visceral organs. We conclude that interferon is an important early component of host resistance to this virus infection.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 186554      PMCID: PMC2190462          DOI: 10.1084/jem.144.5.1305

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  6 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Effect of repeated inoculation of interferon preparations on infection of mice with encephalomyocarditis virus.

Authors:  I Gresser; C Bourali; M T Thomas; E Falcoff
Journal:  Proc Soc Exp Biol Med       Date:  1968-02

3.  A method for the large scale production of potent interferon preparations.

Authors:  M G Tovey; J Begon-Lours; I Gresser
Journal:  Proc Soc Exp Biol Med       Date:  1974-07

4.  [Effect of an anti-interferon serum on experimental viral pathogenicity in vivo].

Authors:  B Fauconnier
Journal:  Pathol Biol (Paris)       Date:  1971 Jun-Jul

5.  [Increase of viral pathogenicity by use of anti-interferon serum in vivo].

Authors:  B Fauconnier
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1970-10-19

6.  Raising antibodies to human leukocyte interferon.

Authors:  K E Mogensen; L Pyhälä; K Cantell
Journal:  Acta Pathol Microbiol Scand B       Date:  1975-10
  6 in total
  76 in total

1.  Initial characterization of a spontaneous interferon secreted during growth and differentiation of Friend erythroleukemia cells.

Authors:  M F Revel; A Kimchi
Journal:  Mol Cell Biol       Date:  1982-12       Impact factor: 4.272

Review 2.  Immunomodulating therapy in experimental myocarditis.

Authors:  A Matsumori; C Kawai
Journal:  Springer Semin Immunopathol       Date:  1989

3.  Alteration of host defense mechanisms by murine cytomegalovirus infection.

Authors:  D K Kelsey; G A Olsen; J C Overall; L A Glasgow
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

4.  Requirement for macrophages for interferon to be effective against encephalomyocarditis virus infection of mice.

Authors:  N Stebbing; K M Dawson; I J Lindley
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

5.  Immunosuppressive effects of lymphocyte (type II) and leucocyte (type I) interferon on primary antibody responses in vivo and in vitro.

Authors:  J L Virelizier; E L Chan; A C Allison
Journal:  Clin Exp Immunol       Date:  1977-11       Impact factor: 4.330

6.  Injection of mice with antibody to interferon renders peritoneal macrophages permissive for vesicular stomatitis virus and encephalomyocarditis virus.

Authors:  F Belardelli; F Vignaux; E Proietti; I Gresser
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

7.  Resistance of lymphocytic choriomeningitis virus to alpha/beta interferon and to gamma interferon.

Authors:  D Moskophidis; M Battegay; M A Bruendler; E Laine; I Gresser; R M Zinkernagel
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  Pilot study of recombinant interferon alpha-2a for treatment of infants with bronchiolitis induced by respiratory syncytial virus.

Authors:  J Portnoy; R Hicks; F Pacheco; L Olson
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

9.  Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver.

Authors:  L G Guidotti; P Borrow; M V Hobbs; B Matzke; I Gresser; M B Oldstone; F V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

10.  Immunomodulatory effects of Panax Ginseng C.A. Meyer in the mouse.

Authors:  Y H Jie; S Cammisuli; M Baggiolini
Journal:  Agents Actions       Date:  1984-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.